MAIA Biotechnology Announces Updated Interim Efficacy Data From Part C Of Its Phase 2 THIO-101 Expansion Trial Evaluating Ateganosine For Advanced Non-Small Cell Lung Cancer; Observed Disease Control Rate Is 88%
Benzinga Newsdesk 23 hours ago
FDANews
Updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial evaluating its novel telomere-targeting therapy, ateganosine, as a third-line (3L) treatment for advanced non-small cell lung cancer (NSCLC). THIO-101 Part C is evaluating additional patients to confirm the strong efficacy data observed in Parts A and B of the study.
The Phase 2 trial assesses advanced NSCLC patients who were nonresponsive or developed resistance and progressed after prior immune checkpoint inhibitor therapy and chemotherapy. Patients are treated with ateganosine 180mg followed by cemiplimab (Libtayo®) in cycles of 21 days. The sequential administration of ateganosine followed by PD-(L)1 inhibition is intended to enhance and prolong the antitumor immune response.
"It is encouraging to see an 88% disease control rate (DCR) as the THIO-101 data continue to mature. DCR serves as an excellent data surrogate for Overall Survival (OS) efficacy according to a historical meta-analysis1 and our own analysis of previous data," said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. "To date, the trial’s combined study data have consistently demonstrated stable disease or better at the first tumor assessment following treatment initiation. Importantly, the Part C interim efficacy results are well aligned with the outcomes observed in Parts A and B, now across a substantially larger patient population. Consistency of the results as our patient pool expands further strengthens the compelling efficacy signals we are seeing for both of our trials in NSCLC."
For Parts A, B, and C of THIO-101 as of October 01, 2026, the observed disease control rate (DCR) for third-line NSCLC patients resistant to chemo and immunotherapy is 88% (38 of 43 patients) in the efficacy evaluable population who had at least one tumor scan after starting treatment. This DCR measure contrasts with reported 25%–35% disease control for standard 3L chemotherapy regimens.1
MAIA has completed enrollment in Part C of its Phase 2 THIO-101 expansion, which enrolled patients in Hungary, Poland, Turkey, Georgia, Romania, Taiwan, and in the United States. Concurrently, an ongoing pivotal Phase 3 clinical trial of third line ateganosine treatment, THIO-104, with the same target population as THIO-101 Part C, is advancing toward regulatory milestones including 2027 interim survival analysis.
